Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)

Dr. Julie E. Bauman

Hematology Oncology | Hematology | Oncology
Medical Faculty Associates, Inc
2150 Pennsylvania Ave Nw, 
Washington, DC 
Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Medical Faculty Associates, Inc
2150 Pennsylvania Ave Nw, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Julie Bauman is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Dr. Bauman is rated as an Elite provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Glioma, Tongue Cancer, Nasopharyngeal Carcinoma, and Tissue Biopsy.

Her clinical research consists of co-authoring 109 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 44 articles and participated in 13 clinical trials in the study of Head and Neck Squamous Cell Carcinoma (HNSCC).

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NM
Hospital Affiliations
George Washington Univ Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

MEDICAL FACULTY ASSOCIATES, INC
2150 Pennsylvania Ave Nw, Washington, DC 20037

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
Immune Modulation by Abemaciclib in HPV-Negative Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized Phase II Window Trial.
Immune Modulation by Abemaciclib in HPV-Negative Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized Phase II Window Trial.
Enrollment Status: Terminated
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: Abemaciclib
Study Phase: Phase 2
Pharmacodynamic Effects and Predictive Biomarkers of Janus Kinases (JAK)/Signal Transducer and Activator of Transcription (STAT) Inhibition With Ruxolitinib in Operable Head and Neck Cancer: a Window Trial
Pharmacodynamic Effects and Predictive Biomarkers of Janus Kinases (JAK)/Signal Transducer and Activator of Transcription (STAT) Inhibition With Ruxolitinib in Operable Head and Neck Cancer: a Window Trial
Enrollment Status: Terminated
Publish Date: October 30, 2024
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Drug, Biological
Study Drugs: Ficlatuzumab, Cetuximab
Study Phase: Phase 2
Randomized, Phase II Study Evaluating Concurrent or Sequential Fixed-Dose Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy in Intermediate or High Risk, Previously Untreated, Locally Advanced Head and Neck Cancer
Randomized, Phase II Study Evaluating Concurrent or Sequential Fixed-Dose Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy in Intermediate or High Risk, Previously Untreated, Locally Advanced Head and Neck Cancer
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug, Radiation
Study Drugs: Pembrolizumab, Cisplatin
Study Phase: Phase 2
Biomarker Modulation by Alpelisib (BYL719) in Transorally Resectable, HPV-Associated HNSCC: A Phase II Window Trial
Biomarker Modulation by Alpelisib (BYL719) in Transorally Resectable, HPV-Associated HNSCC: A Phase II Window Trial
Enrollment Status: Terminated
Publish Date: April 17, 2024
Intervention Type: Other, Drug, Procedure
Study Drug: Alpelisib
Study Phase: Phase 2
Clinical Study of Avmacol® for Detoxification of Tobacco Carcinogens in Heavy Smokers
Clinical Study of Avmacol® for Detoxification of Tobacco Carcinogens in Heavy Smokers
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Drug, Other
Study Phase: Early Phase 1
Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cetuximab, Docetaxel
Study Phase: Phase 2
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: April 03, 2023
Intervention Type: Drug
Study Drugs: CDX-3379, Cetuximab
Study Phase: Phase 2
A Single Arm Phase II Study of Cemiplimab-rwlc in Immunocompromised Patients With Unresectable Locally Recurrent and/or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
A Single Arm Phase II Study of Cemiplimab-rwlc in Immunocompromised Patients With Unresectable Locally Recurrent and/or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
Enrollment Status: Terminated
Publish Date: November 04, 2022
Intervention Type: Drug
Study Drug: Cemiplimab-RWLC
Study Phase: Phase 2
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
Enrollment Status: Terminated
Publish Date: January 03, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: December 09, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 12 Less Clinical Trials

109 Total Publications

Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer.
Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 27, 2025
Similar Doctors
Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Ranee Mehra
Oncology | Hematology
Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Ranee Mehra
Oncology | Hematology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (35.1 miles away)
410-328-1230
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ranee Mehra is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Mehra is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Tongue Cancer, and Glossectomy. Dr. Mehra is currently accepting new patients.

Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. David Sidransky
Oncology | Otolaryngology
Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. David Sidransky
Oncology | Otolaryngology
720 Rutland Ave, 
Baltimore, MD 
 (36.8 miles away)
410-502-5153
Languages Spoken:
English
See accepted insurances

David Sidransky is an Oncologist and an Otolaryngologist in Baltimore, Maryland. Dr. Sidransky is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Adenoid Cystic Carcinoma, Salivary Gland Tumors, and Polymorphous Low Grade Adenocarcinoma.

Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Vassiliki Saloura
Oncology
Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Vassiliki Saloura
Oncology

Johns Hopkins University

5759 Cedar Ln, 
Columbia, MD 
 (23.3 miles away)
443-718-3738
Languages Spoken:
English
See accepted insurances

Vassiliki Saloura is an Oncologist in Columbia, Maryland. Dr. Saloura is rated as an Advanced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Wolf-Hirschhorn Syndrome, Glioma, and Tongue Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bauman's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 35 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile